Cutia Therapeutics (HKG:2487)
Hong Kong
· Delayed Price · Currency is HKD 5.00
+0.29 (6.16%)
At close: Mar 10, 2026
Cutia Therapeutics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 250.33 | 279.62 | 137.62 | 11.37 | 2.04 |
| Revenue Growth (YoY) | 25.89% | 103.17% | 1110.83% | 457.70% | - |
| Cost of Revenue | 125.14 | 136.15 | 66.62 | 3.43 | 0.43 |
| Gross Profit | 125.19 | 143.46 | 71.01 | 7.94 | 1.61 |
| Selling, General & Admin | 390.35 | 405.53 | 394.2 | 136.39 | 71.04 |
| Research & Development | 178.92 | 199.05 | 215.71 | 180.76 | 110.56 |
| Operating Expenses | 576.88 | 605.01 | 610.66 | 317.14 | 181.6 |
| Operating Income | -451.69 | -461.54 | -539.65 | -309.2 | -179.99 |
| Interest Expense | -10.96 | -10.86 | -4.48 | -1.73 | -0.56 |
| Interest & Investment Income | 7.65 | 11.81 | 23.41 | 17.37 | 6.11 |
| Currency Exchange Gain (Loss) | 0.34 | 2.34 | 20.8 | 73.98 | -23.03 |
| Other Non Operating Income (Expenses) | -31.56 | 3.32 | -11.82 | -16.83 | 3.4 |
| EBT Excluding Unusual Items | -486.23 | -454.93 | -511.74 | -236.41 | -194.06 |
| Gain (Loss) on Sale of Investments | 16.27 | 21.99 | 2.47 | 7.68 | -5.2 |
| Gain (Loss) on Sale of Assets | -1.33 | -0.36 | -0.25 | - | - |
| Other Unusual Items | -0.99 | -0.51 | -1,454 | -327.1 | -120.33 |
| Pretax Income | -472.27 | -433.81 | -1,964 | -555.84 | -319.58 |
| Net Income | -472.27 | -433.81 | -1,964 | -555.84 | -319.58 |
| Net Income to Common | -472.27 | -433.81 | -1,964 | -555.84 | -319.58 |
| Shares Outstanding (Basic) | 314 | 307 | 205 | 80 | 80 |
| Shares Outstanding (Diluted) | 314 | 307 | 205 | 80 | 80 |
| Shares Change (YoY) | 2.95% | 50.13% | 155.62% | - | - |
| EPS (Basic) | -1.50 | -1.41 | -9.60 | -6.94 | -3.99 |
| EPS (Diluted) | -1.50 | -1.41 | -9.60 | -6.94 | -3.99 |
| Free Cash Flow | -389.88 | -465.56 | -437.04 | -370.54 | -184.2 |
| Free Cash Flow Per Share | -1.24 | -1.52 | -2.14 | -4.63 | -2.30 |
| Gross Margin | 50.01% | 51.31% | 51.60% | 69.84% | 79.00% |
| Operating Margin | -180.44% | -165.06% | -392.13% | -2720.43% | -8831.45% |
| Profit Margin | -188.66% | -155.15% | -1426.91% | -4890.34% | -15681.11% |
| Free Cash Flow Margin | -155.75% | -166.50% | -317.56% | -3260.10% | -9038.08% |
| EBITDA | -421.41 | -432.92 | -508.8 | -298.43 | -174.06 |
| EBITDA Margin | -168.34% | -154.83% | - | - | - |
| D&A For EBITDA | 30.27 | 28.62 | 30.85 | 10.78 | 5.93 |
| EBIT | -451.69 | -461.54 | -539.65 | -309.2 | -179.99 |
| EBIT Margin | -180.44% | -165.06% | - | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.